Sugi Predict

Sugi Predict / Compounds / SCHEMBL985090

SCHEMBL985090

SCHEMBL985090

CC(C)(C)OC(=O)N1CC(n2cc(I)cn2)C1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MPO P05164 1/20 0.46
▸ DDB1 Q16531 1/20 0.43
▸ CRBN Q96SW2 1/20 0.43
▸ NR1H2 P55055 1/20 0.40
▸ GPR119 Q8TDV5 5/20 0.39
▸ RET P07949 2/20 0.39
▸ USP30 Q70CQ3 2/20 0.39
▸ SCN9A Q15858 1/20 0.38
▸ PSEN1 P49768 1/20 0.37
▸ PSEN2 P49810 1/20 0.37
▸ APH1B Q8WW43 1/20 0.37
▸ NCSTN Q92542 1/20 0.37
▸ APH1A Q96BI3 1/20 0.37
▸ PSENEN Q9NZ42 1/20 0.37
▸ NAMPT P43490 1/20 0.37
▸ IRAK4 Q9NWZ3 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15270991 0.90 MPO (0.40) MPODDB1CRBNNR1H2GPR119
SCHEMBL26388949 0.90 DDB1 (0.49) MPODDB1CRBNGPR119USP30
SCHEMBL1425565 0.90 NR1H2 (0.48) MPODDB1CRBNNR1H2GPR119
SCHEMBL16267942 0.90 DDB1 (0.49) MPODDB1CRBNGPR119USP30
SCHEMBL15273089 0.90 NR1H2 (0.48) MPODDB1CRBNNR1H2GPR119
SCHEMBL15273480 0.89 MPO (0.40) MPODDB1CRBNNR1H2GPR119
SCHEMBL26388951 0.88 FGFR3 (0.43) MPODDB1CRBNGPR119USP30
SCHEMBL16899840 0.88 FGFR3 (0.43) MPODDB1CRBNGPR119USP30
SCHEMBL15270564 0.88 MPO (0.49) MPODDB1CRBNNR1H2GPR119
SCHEMBL27940265 0.87 MPO (0.38) MPODDB1CRBNNR1H2GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085053-A1 BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND THE USE THEREOF BEONE MEDICINES I GMBH (CH) 2026-03-26 — — US disclosed
WO-2025076285-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME DELPHIA THERAPEUTICS, INC. (US) 2025-04-10 — — WO disclosed
WO-2023192901-A9 QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS ESCIENT PHARMACEUTICALS, INC. (US) 2023-12-14 — — WO disclosed
WO-2023192901-A1 QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS ESCIENT PHARMACEUTICALS, INC. (US) 2023-10-05 — — WO disclosed
EP-3957633-A1 A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF Hinova Pharmaceuticals Inc. (CN) 2022-02-23 — — EP disclosed
US-20210253571-A1 AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR WUXI LIFE FOUNTAIN BIOTECH CO., LTD (CN) 2021-08-19 — — US disclosed
EP-3825314-A1 AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR Medshine Discovery Inc. (CN) 2021-05-26 — — EP disclosed
CN-111825657-A Dual-function chimeric heterocyclic compound for targeted degradation of androgen receptor and application thereof 成都海创药业有限公司 2020-10-27 — — CN disclosed
WO-2020211822-A1 A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF 成都海创药业有限公司 2020-10-22 — — WO disclosed
WO-2020211822-A1 A CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DEGRADATION OF ANDROGEN RECEPTORS AND USE THEREOF 成都海创药业有限公司 2020-10-22 — — WO disclosed
EP-2356116-A1 SUBSTITUTED PYRROLOÝ2,3-B¨-PYRIDINES AND-PYRAZINES OSI Pharmaceuticals, Inc. (US) 2011-08-17 — — EP disclosed
US-20110059936-A1 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-10 — — US disclosed
US-7872031-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-18 — — US disclosed
EP-2265270-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2010-12-29 — — EP disclosed
WO-2010059771-A1 SUBSTITUTED PYRROLO[2,3-B]-PYRIDINES AND-PYRAZINES OSI PHARMACEUTICALS, INC. (US) 2010-05-27 — — WO disclosed
WO-2010059771-A1 SUBSTITUTED PYRROLO[2,3-B]-PYRIDINES AND-PYRAZINES OSI PHARMACEUTICALS, INC. (US) 2010-05-27 — — WO disclosed
EP-2004625-B1 C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS VERTEX PHARMA (US) 2009-12-30 — — EP disclosed
WO-2009099982-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2009-08-13 — — WO disclosed
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. 2009-08-06 — — US disclosed
US-20070254868-A1 C-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-11-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260085053-A1 BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND THE USE THEREOF SIK1, CHUK, SIK2 MPO 1542/4885DDB1 2891/4885CRBN 1364/4885
US-20110059936-A1 C-MET PROTEIN KINASE INHIBITORS MET, PRKCH, ABL1 MPO 4536/4885DDB1 1825/4885CRBN 235/4885
US-20210253571-A1 AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR MET, FGFR1, FGFR2 MPO 4551/4885DDB1 3567/4885CRBN 902/4885
US-20070254868-A1 C-MET protein kinase inhibitors MET, PRKCH, ABL1 MPO 4536/4885DDB1 1825/4885CRBN 235/4885
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS ERBB2, ABL2, TIE1 MPO 4641/4885DDB1 3218/4885CRBN 2509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.